Nilotinib Viatris (Nilotinib)

Nilotinib selectively blocks the BCR‑ABL tyrosine kinase by binding to its ATP‑binding site, which halts downstream signaling pathways responsible for uncontrolled proliferation of leukemic cells, leading to reduced tumor growth and increased cell death.

The dose of Nilotinib Viatris is individualized by the prescribing physician based on clinical guidelines, disease phase, patient weight, liver function, and potential drug interactions. No fixed regimen is provided here.

Safety of nilotinib in pregnancy or while breastfeeding has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and alternative therapies are considered when possible.

To order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Nilotinib is a second‑generation BCR‑ABL inhibitor with higher potency and activity against many imatinib‑resistant mutations. It generally offers deeper molecular responses but may have a different safety profile, requiring monitoring for cardiovascular and metabolic effects.

Store Nilotinib Viatris tablets at ambient temperature, preferably below 25 °C, in the original container, protected from moisture and direct sunlight. Do not refrigerate or freeze the product.

Nilotinib Viatris is taken orally as a tablet with a full glass of water. It is usually administered on an empty stomach, at least one hour before or two hours after a meal, to ensure optimal absorption.

Serious risks include cardiovascular events such as arterial occlusion, severe liver injury (hepatotoxicity), and pancreatitis. Patients should be monitored regularly for heart health, liver function tests, and pancreatic enzyme levels.

Patients with known hypersensitivity to nilotinib or any component of the formulation, those with uncontrolled severe cardiac disease, significant hepatic impairment, or a history of pancreatitis should avoid using Nilotinib Viatris.